Trial Profile

A DOUBLE BLIND, RANDOMIZED, PARALLEL-GROUP, SINGLE-DOSE, 2-ARM, COMPARATIVE PHARMACOKINETIC STUDY OF PF-06439535 (CN) AND BEVACIZUMAB SOURCED FROM EUROPEAN UNION ADMINISTERED TO CHINESE HEALTHY MALE VOLUNTEERS

Status: Withdrawn prior to enrolment

Phase of Trial: Phase I

Latest Information Update: 29 Apr 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bevacizumab (Primary)
Indications Cervical cancer; Colorectal cancer; Glioblastoma; Male breast cancer; Non-small cell lung cancer; Renal cancer
Focus Pharmacokinetics
Sponsors Pfizer

23 Apr 2021 Status changed from not yet recruiting to withdrawn prior to enrolment after a comprehensive review of the biosimilars market and the company's global manufacturing network.
23 Jun 2020 Planned End Date changed from 30 Nov 2020 to 10 Jul 2021.
23 Jun 2020 Planned primary completion date changed from 30 Nov 2020 to 10 Jul 2021.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com